ClinicalTrials.gg
CompletedNCT03709823Updated May 18, 2020Results posted

Trial of Cytisine in Adult Smokers

A Phase 2 interventional study of Cytisine and Placebo Comparator in Smoking Cessation, sponsored by Achieve Life Sciences. Completed at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-05-18.

Sponsored by Achieve Life Sciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
254
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 22 studies testing cytisine in Smoking Cessation — 3 open to participants now, 5 under way, 1 of them phase 3. cytisine · Smoking Cessation.

Enrollment
11th of 22
254 · median 202
Started
2018
with 1 other
Phase 2
3 of 22
1 open now
Registered
7th of 22
by date
Lead sponsor
10 of 22
Achieve Life Sciences

Among the 22 studies testing cytisine in Smoking Cessation, this one is the 11th largest by enrollment, is one of 2 that started in 2018, is one of 3 in phase 2, and was the 7th registered.

Smoking Cessation

1,582 studies on the registry are indexed under Smoking Cessation; 198 are open to participants now.

Browse Smoking Cessation studies →

Open to participants now

3 of the 22 studies testing cytisine in Smoking Cessation are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About cytisine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 137 Smoking Cessation studies recruiting now, 93 (68%) set no upper age limit and 37 (27%) stop at 75 or younger; 6 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing cytisine in Smoking Cessation, or all of them as a file.
02

Study summary

This placebo-controlled Phase 2b trial is being conducted at sites within the United States (US) to evaluate the effectiveness cytisine dosage (1.5 mg, 3.0 mg) and administration schedule (commercial titration versus simplified 3 times daily [TID] schedule) within a 25-day treatment period.

03

Conditions studied

  • Smoking Cessation

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects, age ≥ 18 years.
  2. Current daily cigarette smokers (averaging ≥ 10 cigarettes per day upon completing a 7-day screening diary) and who intend to quit smoking.
  3. Expired air carbon monoxide (CO) ≥ 10 parts per million (ppm).
  4. Failed at least one previous attempt to stop smoking with or without therapeutic support.
  5. Willing to initiate study treatment on the day after randomization and set a quit date that is 5-7 days after starting treatment.
  6. Willing to actively participate in the study's smoking cessation behavioral support provided throughout the study.
  7. Able to fully understand all study requirements, willing to participate, comply with dosing schedule, and sign the Form.

Exclusion criteria

Exclusion Criteria:

  1. Known to cytisine or any of the .
  2. Positive urinary drugs of abuse screen, determined within 28 days before the first dose of cytisine.
  3. abnormal serum chemistry or hematology values within 28 days of randomization (i.e. requiring treatment).
  4. Clinically significant abnormalities in 12-lead (ECG) determined after minimum of 5 minutes in supine position within 28 days of randomization (i.e. requiring treatment or further assessment).
  5. (BMI) classification for being underweight (\< 18.5 kg/m\^2) or having ≥ Class 2 obesity (≥ 35 kg/m\^2).
  6. Recent history (within 3 months) of acute myocardial infarction, unstable angina, stroke, cerebrovascular incident or hospitalization for congestive heart failure.
  7. Current uncontrolled hypertension (blood pressure ≥ 160/100 mmHg).
  8. Documented diagnosis of schizophrenia or bipolar psychiatric illness; currently psychotic; having suicidal ideation (Suicide Behaviors Questionnaire-Revised [SBQ-R] score ≥ 7); or current symptoms of moderate to severe depression (Hospital Anxiety and Depression Scale [HADS] score ≥ 11).
  9. Renal impairment defined as a (CrCl) \< 60 mL/min (estimated with the Cockroft-Gault equation) or hepatic impairment defined as (ALT) or aspartate aminotransferase (AST) > 2.0 times the (ULN).
  10. Women who are pregnant or breast-feeding.
  11. Male or Female subjects of child bearing potential who do not agree to use acceptable methods of during the study treatment period.
  12. Participation in a clinical study with an drug within 4 weeks of randomization.
  13. Treatment with other smoking cessation medications (bupropion, varenicline, nortriptyline, or any nicotine replacement therapy [NRT]) within 4 weeks of randomization or planned use of these other smoking cessation medications during the study.
  14. Use within 2 weeks of randomization or planned use during the study of non-cigarette nicotine products (e-cigarettes, pipe tobacco, cigars, snuff, chewing tobacco, hookah) or marijuana vaping or smoking.
  15. Any other reason that the investigator views the subject should not participate or would be unable to fulfill the requirements for the study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
254 participants (actual)

Study arms

  • Experimental
    1.5 mg Cytisine, Commercial Schedule

    1.5 mg cytisine dose using the commercial 25-day titration schedule + behavioral support

    Drug: Cytisine · Behavioral: Behavioral support

  • Experimental
    3.0 mg Cytisine, Commercial Schedule

    3.0 mg cytisine dose using the commercial 25-day titration schedule + behavioral support

    Drug: Cytisine · Behavioral: Behavioral support

  • Placebo comparator
    Placebo, Commercial Schedule

    Placebo tablets using the commercial 25-day titration schedule + behavioral support

    Drug: Placebo Comparator · Behavioral: Behavioral support

  • Experimental
    1.5 mg Cytisine, TID Schedule

    1.5 mg cytisine dose for 25 days using a simplified 3 times daily (TID) schedule + behavioral support

    Drug: Cytisine · Behavioral: Behavioral support

  • Experimental
    3.0 mg Cytisine, TID Schedule

    3.0 mg cytisine dose for 25 days using a simplified TID schedule + behavioral support

    Drug: Cytisine · Behavioral: Behavioral support

  • Placebo comparator
    Placebo, TID Schedule

    Placebo tablets for 25 days using a simplified TID schedule + behavioral support

    Drug: Placebo Comparator · Behavioral: Behavioral support

Interventions

  • film coated tablet containing 1.5 mg cytisine in a single tablet

  • DrugPlacebo Comparator

    1.5 mg cellulose powder to match final weight of the cytisine tablet

  • BehavioralBehavioral support

    12 behavioral support sessions by a qualified staff member plus supportive literature and online resources

06

What researchers measure

Primary outcomes

  1. Primary Efficacy Analysis of Primary Outcome Measure: Percentage of Expected Cigarettes Smoked Per Participant During Study Treatment

    The daily cigarette counts (number of cigarettes smoked in the past 24 hours) were self-reported by participants in the diary. Percentage of expected cigarettes smoked was computed for each participant at the end of treatment (cigarette score), based on daily cigarette counts during treatment vs the screening period. The percentage of expected cigarettes smoked was computed as Y = (100 x N) / (T x R) where N represents total number of cigarettes smoked each day over the treatment period from Day 1 to Day 25; T represents number of post-randomization days where number of cigarettes smoked is recorded; and R represents the average number of cigarettes smoked daily over the 7-day screening period as baseline. T\*R represents the total number of cigarettes that would have been smoked without intervention over the number of recorded days. Separate statistical analyses were performed for the two cytisine administration schedules (commercial and TID).

    Time frame: Day 1 through Day 25

  2. Sensitivity Analysis of Primary Outcome Measure: Analysis for Percentage of Expected Cigarettes Smoked Versus Pooled Placebo Arms, Commercial Schedule

    The daily cigarette counts (number of cigarettes smoked in the past 24 hours) were self-reported by participants in the diary. Percentage of expected cigarettes smoked was computed for each participant at the end of treatment (cigarette score), based on daily cigarette counts during treatment vs the screening period. (See Outcome Measure 1 description for details.) The sensitivity analysis of the primary outcome measure was only performed if results of "Statistical Analysis 5" for Outcome Measure 1 demonstrated the placebo treatment arms (commercial and TID) were not significantly different, and so could be pooled. Separate statistical analyses were performed for the two cytisine administration schedules (commercial and TID).

    Time frame: Day 1 through Day 25

  3. Sensitivity Analysis of Primary Outcome Measure: Analysis for Percentage of Expected Cigarettes Smoked Versus Pooled Placebo Arms, TID Schedule

    The daily cigarette counts (number of cigarettes smoked in the past 24 hours) were self-reported by participants in the diary. Percentage of expected cigarettes smoked was computed for each participant at the end of treatment (cigarette score), based on daily cigarette counts during treatment vs the screening period. (See Outcome Measure 1 description for details.) The sensitivity analysis of the primary outcome measure was only performed if results of "Statistical Analysis 5" for Outcome Measure 1 demonstrated the placebo treatment arms (commercial and TID) were not significantly different, and so could be pooled. Separate statistical analyses were performed for the two cytisine administration schedules (commercial and TID).

    Time frame: Day 1 through Day 25

07

Results

Posted May 18, 2020

Participant flow

Participant flow — Overall Study
Milestone1.5 mg Cytisine, Commercial Schedule3.0 mg Cytisine, Commercial SchedulePlacebo, Commercial Schedule1.5 mg Cytisine, TID Schedule3.0 mg Cytisine, TID SchedulePlacebo, TID Schedule
Started515025525026
Completed484522504926
Not completed353210
Withdrew: Adverse event001000
Withdrew: Lost to follow-up222110
Withdrew: Withdrawal by subject130000
Withdrew: Other, not specified000100

Outcome measures

PrimaryPrimary Efficacy Analysis of Primary Outcome Measure: Percentage of Expected Cigarettes Smoked Per Participant During Study Treatment

The daily cigarette counts (number of cigarettes smoked in the past 24 hours) were self-reported by participants in the diary. Percentage of expected cigarettes smoked was computed for each participant at the end of treatment (cigarette score), based on daily cigarette counts during treatment vs the screening period. The percentage of expected cigarettes smoked was computed as Y = (100 x N) / (T x R) where N represents total number of cigarettes smoked each day over the treatment period from Day 1 to Day 25; T represents number of post-randomization days where number of cigarettes smoked is recorded; and R represents the average number of cigarettes smoked daily over the 7-day screening period as baseline. T\*R represents the total number of cigarettes that would have been smoked without intervention over the number of recorded days. Separate statistical analyses were performed for the two cytisine administration schedules (commercial and TID).

Time frame:
Day 1 through Day 25
Reported as:
Least squares mean · percentage of cigarettes smoked
Primary Efficacy Analysis of Primary Outcome Measure: Percentage of Expected Cigarettes Smoked Per Participant During Study Treatment
percentage of cigarettes smoked1.5 mg Cytisine, Commercial Schedule3.0 mg Cytisine, Commercial SchedulePlacebo, Commercial Schedule1.5 mg Cytisine, TID Schedule3.0 mg Cytisine, TID SchedulePlacebo, TID Schedule
Primary Efficacy Analysis of Primary Outcome Measure: Percentage of Expected Cigarettes Smoked Per Participant During Study Treatment26.62 ± 3.08525.04 ± 3.12347.10 ± 4.41729.40 ± 3.04632.50 ± 3.10535.30 ± 4.392
Statistical analysis
  • 1.5 mg Cytisine, Commercial Schedule vs Placebo, Commercial Schedule · ANOVA · p = 0.0002 (Based on analysis of variance models with percent of expected cigarettes smoked as the dependent variable, treatment and body mass index class as main fixed effects, with covariate of baseline cigarettes.) · Ls mean difference vs. placebo: -20.48 · 95% CI -31.141 to -9.821
  • 3.0 mg Cytisine, Commercial Schedule vs Placebo, Commercial Schedule · ANOVA · p = < 0.0001 (Based on analysis of variance models with percent of expected cigarettes smoked as the dependent variable, treatment and body mass index class as main fixed effects, with covariate of baseline cigarettes.) · Ls mean difference vs. placebo: -22.07 · 95% CI -32.791 to -11.342
  • 1.5 mg Cytisine, TID Schedule vs Placebo, TID Schedule · ANOVA · p = 0.2708 (Based on analysis of variance models with percent of expected cigarettes smoked as the dependent variable, treatment and body mass index class as main fixed effects, with covariate of baseline cigarettes.) · Ls mean difference vs. placebo: -5.90 · 95% CI -16.463 to 4.660
  • 3.0 mg Cytisine, TID Schedule vs Placebo, TID Schedule · ANOVA · p = 0.6018 (Based on analysis of variance models with percent of expected cigarettes smoked as the dependent variable, treatment and body mass index class as main fixed effects, with covariate of baseline cigarettes.) · Ls mean difference vs. placebo: -2.81 · 95% CI -13.438 to 7.820
  • Placebo, Commercial Schedule vs Placebo, TID Schedule · ANOVA · p = 0.1025 (Based on analysis of variance models with percent of expected cigarettes smoked as the dependent variable, treatment and body mass index class as main fixed effects, with covariate of baseline cigarettes.) · Ls mean difference vs. commercial sched.: -12.17 · 95% CI -26.869 to 2.535
PrimarySensitivity Analysis of Primary Outcome Measure: Analysis for Percentage of Expected Cigarettes Smoked Versus Pooled Placebo Arms, Commercial Schedule

The daily cigarette counts (number of cigarettes smoked in the past 24 hours) were self-reported by participants in the diary. Percentage of expected cigarettes smoked was computed for each participant at the end of treatment (cigarette score), based on daily cigarette counts during treatment vs the screening period. (See Outcome Measure 1 description for details.) The sensitivity analysis of the primary outcome measure was only performed if results of "Statistical Analysis 5" for Outcome Measure 1 demonstrated the placebo treatment arms (commercial and TID) were not significantly different, and so could be pooled. Separate statistical analyses were performed for the two cytisine administration schedules (commercial and TID).

Time frame:
Day 1 through Day 25
Reported as:
Least squares mean · percentage of expected cigarettes smoked
Sensitivity Analysis of Primary Outcome Measure: Analysis for Percentage of Expected Cigarettes Smoked Versus Pooled Placebo Arms, Commercial Schedule
percentage of expected cigarettes smoked1.5 mg Cytisine, Commercial Schedule3.0 mg Cytisine, Commercial SchedulePooled Placebo
Sensitivity Analysis of Primary Outcome Measure: Analysis for Percentage of Expected Cigarettes Smoked Versus Pooled Placebo Arms, Commercial Schedule26.68 ± 3.06525.08 ± 3.10041.29 ± 3.099
Statistical analysis
  • 1.5 mg Cytisine, Commercial Schedule vs Pooled Placebo · ANOVA · p = 0.0010 (Based on analysis of variance models with percent of expected cigarettes smoked as the dependent variable, treatment and body mass index class as main fixed effects, with covariate of baseline cigarettes.) · Ls mean difference vs. placebo: -14.61 · 95% CI -23.216 to -6.009
  • 3.0 mg Cytisine, Commercial Schedule vs Pooled Placebo · ANOVA · p = 0.0003 (Based on analysis of variance models with percent of expected cigarettes smoked as the dependent variable, treatment and body mass index class as main fixed effects, with covariate of baseline cigarettes.) · Ls mean difference vs. placebo: -16.20 · 95% CI -24.862 to -7.548
PrimarySensitivity Analysis of Primary Outcome Measure: Analysis for Percentage of Expected Cigarettes Smoked Versus Pooled Placebo Arms, TID Schedule

The daily cigarette counts (number of cigarettes smoked in the past 24 hours) were self-reported by participants in the diary. Percentage of expected cigarettes smoked was computed for each participant at the end of treatment (cigarette score), based on daily cigarette counts during treatment vs the screening period. (See Outcome Measure 1 description for details.) The sensitivity analysis of the primary outcome measure was only performed if results of "Statistical Analysis 5" for Outcome Measure 1 demonstrated the placebo treatment arms (commercial and TID) were not significantly different, and so could be pooled. Separate statistical analyses were performed for the two cytisine administration schedules (commercial and TID).

Time frame:
Day 1 through Day 25
Reported as:
Least squares mean · percentage of expected cigarettes smoked
Sensitivity Analysis of Primary Outcome Measure: Analysis for Percentage of Expected Cigarettes Smoked Versus Pooled Placebo Arms, TID Schedule
percentage of expected cigarettes smoked1.5 mg Cytisine, TID Schedule3.0 mg Cytisine, TID SchedulePooled Placebo
Sensitivity Analysis of Primary Outcome Measure: Analysis for Percentage of Expected Cigarettes Smoked Versus Pooled Placebo Arms, TID Schedule29.29 ± 3.29132.41 ± 3.35541.71 ± 3.358
Statistical analysis
  • 1.5 mg Cytisine, TID Schedule vs Pooled Placebo · ANOVA · p = 0.0091 (Based on analysis of variance models with percent of expected cigarettes smoked as the dependent variable, treatment and body mass index class as main fixed effects, with covariate of baseline cigarettes.) · Ls mean difference vs. placebo: -12.41 · 95% CI -21.695 to -3.135
  • 3.0 mg Cytisine, TID Schedule vs Pooled Placebo · ANOVA · p = 0.0518 (Based on analysis of variance models with percent of expected cigarettes smoked as the dependent variable, treatment and body mass index class as main fixed effects, with covariate of baseline cigarettes.) · Ls mean difference vs. placebo: -9.30 · 95% CI -18.667 to 0.075

Adverse events

Collected over From 1st dose of study drug through Week 8 (± 3 days) post-randomization. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
1.5 mg Cytisine, Commercial Schedule0/51 (0%)0/51 (0%)16/51 (31.4%)
3.0 mg Cytisine, Commercial Schedule0/50 (0%)0/50 (0%)16/50 (32%)
Placebo, Commercial Schedule0/25 (0%)0/25 (0%)5/25 (20%)
1.5 mg Cytisine, TID Schedule0/52 (0%)0/52 (0%)15/52 (28.8%)
3.0 mg Cytisine, TID Schedule0/50 (0%)0/50 (0%)14/50 (28%)
Placebo, TID Schedule0/26 (0%)0/26 (0%)8/26 (30.8%)
Most frequent other events
Most frequent other events
Event1.5 mg Cytisine, Commercial Schedule3.0 mg Cytisine, Commercial SchedulePlacebo, Commercial Schedule1.5 mg Cytisine, TID Schedule3.0 mg Cytisine, TID SchedulePlacebo, TID Schedule
NauseaGastrointestinal disorders5/513/501/251/523/504/26
Upper respiratory tract infectionInfections and infestations3/512/503/255/523/504/26
Abnormal dreamsPsychiatric disorders4/517/501/254/523/500/26
HeadacheNervous system disorders1/511/500/256/522/502/26
AnxietyPsychiatric disorders1/511/500/250/521/503/26
InsomniaPsychiatric disorders3/514/501/254/523/500/26
GastroenteritisInfections and infestations1/510/500/252/521/502/26
CoughRespiratory, thoracic and mediastinal disorders0/510/500/250/520/502/26
ConstipationGastrointestinal disorders0/510/500/251/523/501/26
FatigueGeneral disorders1/512/501/253/521/501/26

Baseline characteristics

Age, Continuous
Age, Continuous(years)1.5 mg Cytisine, Commercial Schedule3.0 mg Cytisine, Commercial SchedulePlacebo, Commercial Schedule1.5 mg Cytisine, TID Schedule3.0 mg Cytisine, TID SchedulePlacebo, TID ScheduleTotal
Mean49.8 ± 11.4650.0 ± 13.2051.0 ± 15.1647.0 ± 13.6746.3 ± 12.8847.0 ± 12.6448.4 ± 13.04
Sex: Female, Male
Sex: Female, Male(Participants)1.5 mg Cytisine, Commercial Schedule3.0 mg Cytisine, Commercial SchedulePlacebo, Commercial Schedule1.5 mg Cytisine, TID Schedule3.0 mg Cytisine, TID SchedulePlacebo, TID ScheduleTotal
Female282014292517133
Male23301123259121
Race (NIH/OMB)
Race (NIH/OMB)(Participants)1.5 mg Cytisine, Commercial Schedule3.0 mg Cytisine, Commercial SchedulePlacebo, Commercial Schedule1.5 mg Cytisine, TID Schedule3.0 mg Cytisine, TID SchedulePlacebo, TID ScheduleTotal
American Indian or Alaska Native0101002
Asian0001113
Native Hawaiian or Other Pacific Islander0000000
Black or African American793137746
White434021374118200
More than one race0000000
Unknown or Not Reported1010103
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)1.5 mg Cytisine, Commercial Schedule3.0 mg Cytisine, Commercial SchedulePlacebo, Commercial Schedule1.5 mg Cytisine, TID Schedule3.0 mg Cytisine, TID SchedulePlacebo, TID ScheduleTotal
Hispanic or Latino51261015
Not Hispanic or Latino454923464926238
Native American1000001
Average Number of Cigarettes Smoked per Day Over 7 Consecutive Days
Average Number of Cigarettes Smoked per Day Over 7 Consecutive Days(cigarettes per day)1.5 mg Cytisine, Commercial Schedule3.0 mg Cytisine, Commercial SchedulePlacebo, Commercial Schedule1.5 mg Cytisine, TID Schedule3.0 mg Cytisine, TID SchedulePlacebo, TID ScheduleTotal
Mean17.6 ± 5.3018.0 ± 5.5116.7 ± 4.2818.0 ± 6.6918.0 ± 6.1218.0 ± 5.9617.8 ± 5.75
08

Study locations

8 sites
  • Clinical Research Consortium
    Tempe, Arizona 85283, United States
  • Los Angeles Clinical Trials
    Burbank, California 91505, United States
  • Central Kentucky Research Associates, LLC
    Lexington, Kentucky 40509, United States
  • Center for Pharmaceutical Research, LLC
    Kansas City, Missouri 64114, United States
  • Rochester Clinical Research, Inc
    Rochester, New York 14609, United States
  • Coastal Carolina Research Center, Inc
    Mount Pleasant, South Carolina 29464, United States
  • Volunteer Research Group
    Knoxville, Tennessee 37920, United States
  • FutureSearch Trails of Dallas, LP
    Dallas, Texas 57231, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Apr 2019, 5 months.

Results were first posted in May 2020, 1 year after primary completion.

Of 51 phase 2 interventional studies under Smoking Cessation, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 60. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2018
First posted
Oct 17, 2018
StartActual
Nov 13, 2018
Primary completionActual
Apr 23, 2019
CompletionActual
Apr 23, 2019
Results first posted
May 18, 2020
Last update
May 18, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03709823
Responsible party
Sponsor
First posted
Oct 17, 2018
Start date
Nov 13, 2018
Primary completion
Apr 23, 2019
Completion
Apr 23, 2019
Results posted
May 18, 2020
Last update
May 18, 2020

Study contacts

Mitchell Nides, PhD
principal investigator · Los Angeles Clinical Trials

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cytisine

Start the discussion